Conditioned Media Co-Culture for Consistent Therapeutic Factor Profiles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing conditioned media and secreted factors lack standardization, leading to inconsistent profiles and undesired side effects when used for therapeutic purposes, particularly in treating diseases like SARS-CoV and COVID-19.
Innovation Solution
A method for producing Consortia Media and Consortia Factors through co-culturing different types of cells, including human and plant stem cells, to create a balanced and consistent secretion of anti-inflammatory and anti-viral factors, which can be administered via inhalation or nebulization to treat respiratory conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cells are cultured in complex culture media to maintain original phenotype, then cell phenotype maintenance is improved, but manufacturing consistency and reliability deteriorate due to lack of standardization
Solution Approach 1:
The patent changes the parameters of culture media by defining specific compositions with controlled concentrations of growth factors, cytokines, and other components. This standardization approach transforms complex, variable media into defined formulations that maintain manufacturing consistency while preserving cell phenotype through optimized parameter sets.
Solution Approach 2:
The patent segments the complex culture media into distinct functional components (base media, growth factors, cytokines, supplements) that can be independently standardized and combined. This segmentation allows each component to be optimized and controlled separately, improving overall manufacturing precision while maintaining the complex functionality needed for phenotype preservation.
2Ease of operation
If cells are isolated from original niche and cultured in vitro, then cell communication study is improved, but cell-cell interaction fidelity deteriorates due to loss of natural environment signals
Solution Approach 1:
The patent uses conditioned media as an intermediary that captures and transfers signaling molecules from cells grown under controlled conditions. This media acts as a mediator that brings natural environment signals to isolated cells in culture, preserving the fidelity of cell-cell interactions while enabling the ease of in vitro analysis.
Solution Approach 2:
The patent employs preliminary conditioning of culture media by exposing it to cells under specific environmental conditions before using it to culture target cells. This preliminary action preloads the media with relevant signaling factors that will be present during the actual cell communication study, ensuring natural environment signals are preserved throughout the experiment.
3Measurement precision
If conditioned media is collected and analyzed for secreted factors, then factor profile characterization is improved, but therapeutic application reliability deteriorates due to inconsistent factor profiles
Solution Approach 1:
The patent applies parameter changes by standardizing the culture conditions, cell density, media composition, and harvesting parameters to produce conditioned media with consistent factor profiles. This control of parameters ensures that the same therapeutic factors are produced with reliable concentrations across different batches, enabling therapeutic application while maintaining measurement precision.
Solution Approach 2:
The patent implements feedback mechanisms by analyzing the factor profiles of conditioned media and using this information to optimize and standardize production parameters. This feedback loop ensures that variations in factor production are detected and corrected, maintaining therapeutic reliability while preserving the ability to precisely characterize factor profiles.
4Ease of operation
If viral infection stimulates cells to produce inflammatory secretory factors, then immune response activation is improved, but disease severity worsens due to augmented inflammation and tissue damage
Solution Approach 1:
The patent extracts the beneficial immune-modulating factors from virus-infected cells by collecting and characterizing the conditioned media. This extraction separates the useful immune response activation from the harmful viral infection process, allowing the factors to be applied therapeutically without the associated tissue damage and disease severity.
Solution Approach 2:
The patent converts the harmful inflammatory response caused by viral infection into a beneficial therapeutic tool by isolating and applying the secretory factors in controlled amounts. The same factors that cause damage during uncontrolled infection are harnessed in a regulated manner to modulate immune responses therapeutically, transforming a harmful process into a beneficial one.
Data Source
AI summary
A technology regarding the production, formulation and use of conditioned media and the factors included therein is disclosed. The conditioned media may be inoculated with animal cells, plant cells and any combination thereof. The inoculations may occur simultaneous or at different times. Cells retrieved from different areas of the animal and/or the plant may also be cultured together to form conditioned media and associated growth factors.